ASH 2017 | New MRD monitoring techniques could be most accurate predictor of relapse in MM patients
The field of multiple myeloma (MM) has long been aware of the importance of minimal residual disease (MRD) monitoring, and the technology used to measure it has matured as of late, becoming able to detect just trace levels of the cancer. Speaking from the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition, held in Atlanta, GA, Bruno Paiva, PhD, of the University of Navarra, Pamplona, Spain, discusses three of the MRD-related abstracts presented at the conference. These include his group’s very promising findings regarding the low relapse rate of patients found to be MRD negative using next generation flow (NGF) detection methods, even in patients with high-risk cytogenetics.
Get great new content delivered to your inboxSign up